(Q34761472)

English

Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters (English)

1 reference

Europe PubMed Central

4 August 2017

author name string

Mong-Liang Lu

1

1 reference

Europe PubMed Central

4 August 2017

Chia-Hui Lin

2

1 reference

Europe PubMed Central

4 August 2017

Yi-Chuan Chen

3

1 reference

Europe PubMed Central

4 August 2017

Huai-Chih Yang

4

1 reference

Europe PubMed Central

4 August 2017

Tzu-Hua Wu

5

1 reference

Europe PubMed Central

4 August 2017

language of work or name

0 references

publication date

31 May 2013

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

8

1 reference

Europe PubMed Central

4 August 2017

5

1 reference

Europe PubMed Central

4 August 2017

e65719

1 reference

Europe PubMed Central

4 August 2017

copyright license

Creative Commons Attribution 4.0 International

31 May 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Serum homocysteine and folate levels in korean schizophrenic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Olanzapine versus other atypical antipsychotics for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Adverse effects of antipsychotic medications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Adverse effects of atypical antipsychotics : differential risk and clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Antipsychotic medications: metabolic and cardiovascular risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Monitoring of olanzapine in serum by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Olanzapine: a basic science update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

7 July 2018

Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0065719

21 January 2018

Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0065719

21 January 2018

A new brief instrument for assessing decisional capacity for clinical research

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0065719

21 January 2018

A study of matrix effects on an LC/MS/MS assay for olanzapine and desmethyl olanzapine

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0065719

21 January 2018

Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0065719

21 January 2018

Simultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0065719

21 January 2018

Determination of Olanzapine in rat brain using liquid chromatography with coulometric detection and a rapid solid-phase extraction procedure.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0065719

21 January 2018

The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0065719

21 January 2018

Elevated homocysteine levels in young male patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0065719

21 January 2018

Homocysteinemia as well as methylenetetrahydrofolate reductase polymorphism are associated with affective psychoses.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0065719

21 January 2018

The effect of glucose and insulin on the activity of methylene tetrahydrofolate reductase and cystathionine-beta-synthase: studies in hepatocytes

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0065719

21 January 2018

Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0065719

21 January 2018

The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0065719

21 January 2018

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0065719

21 January 2018

Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669135

26 October 2018

Schizophrenia and impaired homocysteine metabolism: a possible association

1 reference

https://pubmed.ncbi.nlm.nih.gov/23741510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum homocysteine, folate level and methylenetetrahydrofolate reductase 677, 1298 gene polymorphism in Korean schizophrenic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23741510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of variable cigarette consumption on the interaction with clozapine and olanzapine

1 reference

https://pubmed.ncbi.nlm.nih.gov/23741510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication

1 reference

https://pubmed.ncbi.nlm.nih.gov/23741510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant

1 reference

https://pubmed.ncbi.nlm.nih.gov/23741510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection

1 reference

https://pubmed.ncbi.nlm.nih.gov/23741510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection

1 reference

https://pubmed.ncbi.nlm.nih.gov/23741510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection

1 reference

https://pubmed.ncbi.nlm.nih.gov/23741510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23741510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0065719

1 reference

Europe PubMed Central

4 August 2017

2013PLoSO...865719L

0 references

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34761472&oldid=1864693434"